Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc. AE trended higher in normal CRP pts taking Tofa compared to placebo @RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa

Long term safety data for bimekizumab (IL17i) in Psa & axSpA Overall as expected; increased infections (esp fungal/candida) & hepatic events No new signals... uveitis flares is interesting Need H2H of IL17's! IXE vs SEC vs BIM @RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA

Are anti CCP3 the new anti CCP2 antibodies? Not yet! Anti-CCP3 associated w/ diagnosis of RA in a population of patients w/ MSK symptoms But… very strong overlap between CCP2 and 3 with only 3.4% positive for CCP3 negative for CCP2 @RheumNow #ACR23 ABST 0389 https://t.co/BHRqCbqEYw

Detectable hs-cTnT at baseline was associated with future MACE HR 5.6, in the hsCRP high→low cohort with high inflammation at baseline, not vice versa. hs-cTnT may provide additional info for assessing CV risk, Weber et al, Abst#0387 https://t.co/M4zyz2tzIO #ACR23 @RheumNow https://t.co/omMgpRzBA5

Does pregnancy affect axSpA imaging? Large study of 381 pts, in the DESIR cohort, f/up of 5 years. Pregnancy did not aggravate imaging of axSpA women compared to prior to pregnancy. @RheumNow #ACR23 Abs#0513 https://t.co/eeGuxGGB5E

#ACR23 Abs 0465 suggests changes in rheums’ rx patterns in context of nationwide abortion restriction, particularly in abortion-restricted states; reproductive-age female pts may have less access to EB treatments like MTX/MMF for rheum dz. https://t.co/QN9C4PjUaN @rheumnow

Non invasive screening for pulmonary involvement in early RA Combination of PFT and Lung 🫁 US: -50% with interstitial or focal changes or pleural effusion on US -58% with abnormal DLCO Correlation w/ higher disease activity. Pathological meaning? @RheumNow ABST 0393 #ACR23 https://t.co/BBcOEgcJK2

@RheumNow PMR Mythbusters: we polled Aussie🇦🇺 rheumatologists How did those motivated enough to answer a PMR/GCA survey fare? Myth: PMR is only proximal - not bad Myth: PMR needs ⬆️ESR/CRP - a bit of work Time to #MakeRheumForPMR @victor_yang1 @CatherineL_Hill #ACR23 ABST0267 https://t.co/Z4ZkDHljOf https://t.co/ssHxOBJFxR

WEAR study: adherence to wearable activity trackers in RA Something that is consistent across all wearable studies is low adherence Here under 50% for PRO + tracking In an already selected population! To implement, we need to make this better? ABSTRACT 0344 @RheumNow #ACR23 https://t.co/csVZlzABGt

Difficult to treat D2T-axSpA (failure > 3 biologics), affects one in five patients exposed to b/tsDMARDs in this national registry. D2T is more common in women, presence of peripheral involvement, psoriasis, depression, Fakih O Abst#0514 #ACR23 @RheumNow https://t.co/OoymZzzQST https://t.co/EpTqS1C61A

Deucravacitinib (TYK2) data has been surprisngly good in SLE Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL Probably my #1 draft pick for "drugs I'm buying right now" @RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp

Year in Review: Dr. P Seo ⭐️Does Pizza consumption favor improved dz activity in RA? If in Italy ➡️ 365 pts w/RA in Milan: 18-65 yo w/ >3 mo dz ➡️Ate 1/2 a pizza > 1x/wk w/ decr in dz activity (SDAI⬇️: -3.6) ➡️Mozzarella & olive oil showed beneficial effects #ACR23 @RheumNow https://t.co/qZTzThI39e

YR in Review: Dr. P Seo ⭐️Sarilumab for relapse of PMR during GC taper: ➡️ab against IL6R ➡️118 pts: ⏺️pred 15 mg/d ⏺️Sari 200 mg/d q2wk/14wk ⏺️52wk pred taper ➡️At wk 52: ⏺️sustained remission: 28% vs 10% ⏺️mean total GC: 777 vs 2044 mg #ACR23 @RheumNow https://t.co/ETVpyuBlZ7

Towards more personalised care in rheumatoid arthritis #ACR23 @RheumNow https://t.co/roxtcX8QHI

There is a high concordance (84.4%) of physician and patient global assessment of psoriatic arthritis disease activity from 538 paired assessments in the ARLAR multinational study, Maroof A et al, Abst #0506 #ACR23 @RheumNow https://t.co/NsT4MNWPVX https://t.co/TfuMj8qMXz